Surrozen, Inc./DE Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Surrozen, Inc./DE (SRZN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 0.89% for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-28.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2022-03-28
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-09-30 was 0.99%, a 200.00% increase year-over-year.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-09-30 was 0.33%.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 0.89%, a 11.25% increase from fiscal 2020.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 0.80%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|
| 2021-12-31 | 0.89% 10-K · filed 2022-03-28 | ||
| 2021-09-30 | 0.99% 10-Q · filed 2021-11-15 | 0.85% 10-Q · filed 2021-11-15 | |
| 2020-12-31 | 0.80% 10-K · filed 2022-03-28 | ||
| 2020-09-30 | 0.33% 10-Q · filed 2021-11-15 | 1.05% 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |